# Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa

> **NCT02644525** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 20 (actual)

## Conditions studied

- Loiasis

## Interventions

- **DRUG:** Imatinib Mesylate
- **DRUG:** Imatinib Mesylate
- **DRUG:** Imatinib Mesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02644525
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-16
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-03-19
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Planned interim analysis demonstrated futility of intervention
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02644525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02644525, "Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02644525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*